Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …
evolving, and this poses a major threat to antibody therapies and currently authorized …
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we
compare neutralization of Omicron BA. 1, BA. 1.1, and BA. 2. BA. 2 RBD has slightly higher …
compare neutralization of Omicron BA. 1, BA. 1.1, and BA. 2. BA. 2 RBD has slightly higher …
Advances and gaps in SARS-CoV-2 infection models
C Muñoz-Fontela, L Widerspick, RA Albrecht… - PLoS …, 2022 - journals.plos.org
The global response to Coronavirus Disease 2019 (COVID-19) is now facing new
challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern …
challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern …
SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization
Mutations in the spike glycoproteins of SARS-CoV-2 variants of concern have independently
been shown to enhance aspects of spike protein fitness. Here, we describe an antibody …
been shown to enhance aspects of spike protein fitness. Here, we describe an antibody …
SARS-CoV-2 Omicron-B. 1.1. 529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
EG Bentley, A Kirby, P Sharma, A Kipar, DF Mega… - BioRxiv, 2021 - biorxiv.org
ABSTRACT COVID-19 is a spectrum of clinical symptoms in humans caused by infection
with SARS-CoV-2. The B. 1.1. 529 Omicron variant is rapidly emerging and has been …
with SARS-CoV-2. The B. 1.1. 529 Omicron variant is rapidly emerging and has been …
Omicron (B. 1.1. 529)-A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein
Abstract Omicron, another SARS-CoV-2 variant, has been recorded and reported as a VoC.
It has already spread across> 30 countries and is a highly mutated variant. We tried to …
It has already spread across> 30 countries and is a highly mutated variant. We tried to …
Nanobodies: robust miniprotein binders in biomedicine
Variable domains of heavy chain-only antibodies (VHH), also known as nanobodies (Nbs),
are monomeric antigen-binding domains derived from the camelid heavy chain-only …
are monomeric antigen-binding domains derived from the camelid heavy chain-only …
[HTML][HTML] A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
J Seow, H Khan, A Rosa, V Calvaresi, C Graham… - Cell Reports, 2022 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is the target for
neutralizing antibodies elicited following both infection and vaccination. While extensive …
neutralizing antibodies elicited following both infection and vaccination. While extensive …
Pathogen-sugar interactions revealed by universal saturation transfer analysis
CJ Buchanan, B Gaunt, PJ Harrison, Y Yang, J Liu… - Science, 2022 - science.org
Many pathogens exploit host cell-surface glycans. However, precise analyses of glycan
ligands binding with heavily modified pathogen proteins can be confounded by overlapping …
ligands binding with heavily modified pathogen proteins can be confounded by overlapping …